780 BRANNAN STREET, SAN FRANCISCO, CA
Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
CFO Departure - Shane Kovacs Leaves Olema Pharmaceuticals
Investor Presentation
Olema Pharmaceuticals Announces Follow-On Public Offering of 10 Million Shares
Other Events
Reports Third Quarter 2025 Financial and Operating Results
Announces New Clinical Trial Agreement to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
FY 2025
Q3
Q2
Q1
FY 2024
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Definitive Proxy Statement
Additional Proxy Materials
Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence